Mark your calendars for the ATRIUM Cardiology Collaborative's Second Annual Spring Symposium, scheduled for Wednesday, April 5, from 5-8 p.m.

About the Event:

The ATRIUM Cardiology Collaborative will offer a two-hour live continuing education program this spring. The program will include a one-hour patient safety continuing education activity on drug safety considerations for oral anticoagulants. Inappropriate use of direct acting oral anticoagulants is unacceptably common. Non-vitamin K oral antagonists have important drug safety considerations often overlooked or misunderstood. Clinicians will understand drug safety considerations and apply them to patient scenarios. The second hour will focus on drug-induced considerations in patients with heart failure. Heart failure (HF) accounts for more than $30 billion of health care costs each year in the United States. Progression of symptoms and/or hospitalizations for many patients with HF may be preventable. One contributor to worsening of the disease is the use of medications that may exacerbate symptoms. Clinicians will learn about medications that can have detrimental effects on this patient population and be prepared to prevent drug-induced HF from occurring.

This ATRIUM continuing education program is an application-based educational activity targeted to pharmacists practicing in all settings and will provide clinicians guidance on drug safety considerations for oral anticoagulants and drug-induced considerations in patients with heart failure.


To register for this event, please complete the online registration form. The cost to register for this event is as follows:

  • Continuing Education Program Only: $20
  • Continuing Education Program Plus Dinner: $35

Learning Objectives:

At the completion of this activity, the participant will be able to:

  1. Describe the significance and prevalence of adverse drug events in patients taking non-Vitamin K antagonist oral anticoagulants.
  2. When given a patient case, identify common drug errors that occur with non-Vitamin K antagonist oral anticoagulants.
  3. Identify important drug interactions with non-Vitamin K antagonist oral anticoagulants and, when given a patient case, appropriately select an alternative anticoagulant.
  4. Distinguish medications that exacerbate heart failure (HF) from those that cause de novo myocardial dysfunction.
  5. Given a medication associated with exacerbation of HF, describe a proposed mechanism for worsening myocardial function.
  6. List general approaches to preventing drug-induced exacerbation of HF.
  7. Given a patient with HF on a medication associated with HF exacerbation, devise a medication therapy plan for preventing further decompensation.


This event will be offered at the following location for the convenience of our faculty, preceptors, and residents:

University of Maryland School of Pharmacy
20 N. Pine Stree, Room N103
Baltimore, MD 21201

The dinner will take place in the Ellen H. Yankellow Grand Atrium located in the lobby of Pharmacy Hall.

For More Information:

More information, including registration, faculty, agenda, and parking and directions, can be found on this website. If you have any additional questions, please contact the Department of Pharmacy Practice and Science (PPS) at (410) 706-7338 or

Accredited by the Accreditation Council for Pharmacy Education The University of Maryland School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Successful completion of this activity requires participants' signature on a signature sheet, participation in the entire activity, and completion of an online activity evaluation survey. Statements of credit will be posted to participants' CPE Monitor profile within three weeks of successful completion of this activity.